Renal Failure Research
In terms of morbidity, mortality, and economic costs, End Stage Renal Disease (ESRD) is among the most serious chronic diseases in the United States. ESRD results from the permanent loss of kidney function and, without a regular course of dialysis or kidney transplantation, the disease is fatal. In 1991 Medicare insured approximately 93% of the 142,488 dialysis patients with kidney failure through the ESRD program established in 1973.
Current work includes:
MTPPI recently announced an NIH grant to fund a study titled "Epoetin Therapy and Survival of Hemodialysis Patients". The abstract of that study is available here
Institute researchers will also be giving a talk at the 2005 National Kidney Foundation meeting in Washington, DC entitled "Making Sense of Retrospective Database Studies- How Much Weight Do We Give to These Studies?" For further information regarding the meeting, click on: http://www.kidney.org/meetings/clinical/pdf/CM05_Physicians.pdf
The Institute is also preparing comments on the rule proposed on 2/4/2005 by the Centers for Medicare and Medicaid Services regarding conditions for coverage: http://www.cms.hhs.gov/cop/3818.pdf. Our comments related to the proposed rule for monitoring claims for erythropoietin is also available here
Recent and upcoming posters:
| Past Activities The following studies were conducted by MTPPI or have been submitted for publication. They examine important health services research and economic issues related to renal failure:
|
Do you have an idea for a research topic? MTPPI is always looking for research topics that can help the community and industry better utilize new medical technologies. Let us know. |
Publications
Some recent publications prepared by the Institute in this field are:
- Improved Survival with Higher Hematocrits: Where is the Evidence?
- Cotter D. Does the evidence for anemia treatment support a survival benefit? Arch Intern Med. 2003 Oct 27; 163(19): 2395-6; author reply 2396-7. No abstract available.
- Cotter DJ. Is the evidence for high hematocrit targets valid? Am J Kidney Dis. 2003 Feb; 41(2): 520; author reply 521. No abstract available.
- Secular trends in recombinant erythropoietin therapy among the U.S. hemodialysis population: 1990-1996
- Psychiatric Illness in Patients with End-Stage Renal Disease
- Excluded from universal coverage: End-stage renal disease patients not covered by Medicare
- Relative risk and economic consequences of inpatient care among renal failure patients
- The effect of insurance status on use of recombinant erythropoietin therapy among end-stage renal disease patients in three states
